Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies
March 16, 2017 17:30 ET
|
Actinium Pharmaceuticals
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
March 07, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
February 28, 2017 07:00 ET
|
Actinium Pharmaceuticals
Allowed patent application claims methods for generating radioimmunoconjugates linked to Actinium-225 Patent expected to expire in July 2030 NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) --...
Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
February 23, 2017 07:00 ET
|
Actinium Pharmaceuticals
ORLANDO, Fla., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted...
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
February 21, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Industry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and...
Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations
February 14, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s Iomab-B drug candidate to the bone marrow transplant...
Actinium Pharmaceuticals to Present at Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference
February 13, 2017 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma
February 13, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
February 09, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma
February 07, 2017 08:00 ET
|
Actinium Pharmaceuticals
- Phase 1 trial will evaluate Actimab-M in treating patients with multiple myeloma who are unresponsive to currently available therapies - Clinical trial initiated at Texas Oncology - Baylor Charles...